RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > FDAAA and the Office of New Drugs: An Interview with Dr. John Jenkins.

FDAAA and the Office of New Drugs: An Interview with Dr. John Jenkins.

Posted 01 May 2009

On 5 March, Dr. John Jenkins, director of the US Food and Drug Administration's Office of New Drugs, took the time to answer some questions on the Food and Drug Administration Amendments Act posed by the RAPS Board of Editors.

 

© 2022 Regulatory Affairs Professionals Society.